Citalopram suppresses thymocyte cytokine production

Journal of Neuroimmunology

Volumn 262, Issue 1-2, 2013, Pages 46-52

  Shenoy, Aparna R ^a   Dehmel, Thomas ^a   Stettner, Mark ^a   Kremer, David ^a   Kieseier, Bernd C ^a   Hartung, Hans Peter ^a   Hofstetter, Harald H ^a  

^a Department of Orthopedic Surgery   (Germany)

Author keywords

5 HTT; Citalopram; Interleukin 17; Serotonin; Thymus

Indexed keywords

CD3 ANTIGEN; CITALOPRAM; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; SEROTONIN;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENCY; FEMALE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; THYMOCYTE;

5-HTT; CITALOPRAM; INTERLEUKIN 17; SEROTONIN; THYMUS;

ANIMALS; CITALOPRAM; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MICE; MICE, INBRED C57BL; THYMOCYTES;

EID: 84884151533     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.06.006     Document Type: Article

References (24)

1. Ahern G.P. 5-HT and the immune system. Curr. Opin. Pharmacol. 2011, 11:29-33.
2. Berger M., Gray J.A., Roth B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009, 60:355-366.
3. Dehmel T., Janke A., Hartung H.P., Goebel H.H., Wiendl H., Kieseier B.C. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol. Dis. 2007, 25:665-674.
4. Fletcher J.M., Lalor S.J., Sweeney C.M., Tubridy N., Mills K.H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010, 162:1-11.
5. Gold R., Lühder F. Interleukin-17 - extended features of a key player in multiple sclerosis. Am. J. Pathol. 2008, 172:8-10.
6. Haak S., Croxford A.L., Kreymborg K., et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 2008, 119:61-69.
7. Hofstetter H.H., Mössner R., Lesch K.P., Linker R.A., Toyka K.V., Gold R. Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE. Clin. Exp. Immunol. 2005, 142:39-44.
8. Hofstetter H.H., Ibrahim S.M., Koczan D., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005, 237:123-130.
9. Hofstetter H.H., Lühder F., Toyka K.V., Gold R. IL-17 production by thymocytes upon CD3 stimulation and costimulation with microbial factors. Cytokine 2007, 34:184-197.
10. Kebir H., Kreymborg K., Ifergan I., et al. Human Th17 lymphocytes promote blood brain disruption and central nervous system inflammation. Nat. Med. 2007, 204:161-170.
11. Kim J.S., Smith-Garvin J.E., Koretzky G.A., Jordan M.S. The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells. J. Exp. Med. 2011, 208:2201-2207.
12. Korn T., Oukka M., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin. Immunol. 2007, 19:362-371.
13. Kubera M., Kenis G., Bosmans E., Scharpe S., Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin 10. Neuropsychopharmacology 2000, 23:89-98.
14. Lock C., Hermans G., Pedotti R., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
15. Marks B.R., Nowyhed H.N., CHoi J.Y., et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat. Immunol. 2009, 10:1132.
16. Mitsonis C.I., Zervas M.I., Potagas M.C., Mitropoulos P.A., Dimopoulos N.P., Sfagos C.A., Papadimitrou G.N., Vassilopoulos D.C. Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. Eur. Neuropsychopharmacol. 2010, 20(2):123-131.
17. Mossner R., Lesch K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 1998, 12:249-271.
18. Sacre S., Medghalchi M., Gregory B., Brennan F., Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010, 62:683-693.
19. Smolianov V., Dehmel T., Kieseier B.C., Hemmer B., Hartung H.P., Hofstetter H.H. Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. Cytokine 2012, 58:231-237.
20. Stettner M., Dehmel T., Mausberg A.K., Köhne A., Rose C.R., Kieseier B.C. Levetiracetam exhibits protective properties on rat Schwann cells in vitro. J. Peripher. Nerv. Syst. 2011, 16:250-260.
21. Tanaka S., Yoshimoto T., Naka T., et al. Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses. J. Immunol. 2009, 183:7523-7530.
22. Vollmar P., Nessler S., Kalluri S.R., Hartung H.P., Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int. J. Neuropsychopharmacol. 2009, 12:525-536.
23. White K.J., Walline C.C., Barker E.L. Serotonin transporters: implications for antidepressant drug development. AAPS J. 2005, 7:E421-E433.
24. Zimmermann C., Weber A., Mausberg A.K., Kieseier B.C., Hartung H.P., Hofstetter H.H. T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes. Clin. Exp. Immunol. 2013, 172:245-253.